Imidocarb dipropionate is an antiparasitic drug used to treat and prevent infestations by various parasites in livestock, particularly cattle, sheep, and goats. It is a synthetic compound with a complex chemical structure. The drug's mechanism of action involves disrupting the energy metabolism of parasites, particularly affecting their respiratory chain. This leads to paralysis and death of the parasites. Imidocarb dipropionate is commonly used to treat and prevent infections by protozoan parasites like Babesia and Theileria, which can cause serious diseases in livestock. Its effectiveness against these parasites makes it a crucial tool in livestock management and disease control. Additionally, imidocarb dipropionate has shown activity against some helminths, although it is not typically considered a primary treatment for these infections. Studies continue to explore the full potential of imidocarb dipropionate, investigating its efficacy against different parasite species, potential side effects, and optimal administration methods. This research is crucial for ensuring the safe and effective use of this important antiparasitic drug in livestock production.'
Imidocarb: One of ANTIPROTOZOAL AGENTS used especially against BABESIA in livestock. Toxicity has been reported.
ID Source | ID |
---|---|
PubMed CID | 21389 |
CHEMBL ID | 427342 |
CHEBI ID | 51804 |
SCHEMBL ID | 203921 |
MeSH ID | M0011050 |
PubMed CID | 114961 |
CHEMBL ID | 1315701 |
SCHEMBL ID | 1142888 |
MeSH ID | M0011050 |
Synonym |
---|
AKOS005449571 |
ksc-19-203 |
KUC108633N |
imidocarbum [inn-latin] |
brn 0964732 |
imidocarb [inn:ban] |
einecs 248-711-7 |
n,n'-bis(3-(4,5-dihydro-1h-imidazol-2-yl)phenyl)urea |
carbanilide, 3,3'-di-2-imidazolin-2-yl- |
urea, n,n'-bis(3-(4,5-dihydro-1h-imidazol-2-yl)phenyl)- |
1,3-bis(3-(2-imidazolin-2-yl)phenyl)harnstoff |
imidocarbo [inn-spanish] |
imidocarbe [inn-french] |
1,3-bis(3-(2-imidazolin-2-yl)phenyl)urea |
TIMTEC1_002508 |
imizad (dipropionate) |
1,3-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea |
nsc51189 |
imidocarb |
n,n'-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea |
imizocarb (dihydrochloride) |
urea, n,n'-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]- |
imizol (dipropionate) |
4a65 (dihydrochloride) |
NCGC00174046-01 |
STK379516 |
27885-92-3 |
imidocarbe |
imidocarbo |
CHEBI:51804 , |
imidocarbum |
HMS1541B22 |
TCMDC-124304 , |
imidocarb (inn) |
imizol [veterinary] (tn) |
D08069 |
mmv665810 |
CHEMBL427342 , |
3,3'-di-2-imidazolin-2-ylcarbanilid |
A819229 |
5-25-11-00011 (beilstein handbook reference) |
unii-8uss3k0vdh |
8uss3k0vdh , |
FT-0601768 |
FD7211 |
SCHEMBL203921 |
KS-5199 |
imidocarb [inn] |
imidocarb [mi] |
imidocarb [mart.] |
3,3'-di-2-imidazolin-2-ylcarbanilide |
bdbm79241 |
cid_114961 |
1,3-bis[3-(2-imidazolin-2-yl)phenyl]urea;propionic acid |
DTXSID0048345 , |
n,n'-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea # |
SCEVFJUWLLRELN-UHFFFAOYSA-N |
1,3-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea;propanoic acid |
mfcd00693581 |
imidocarbum; imidocarbe; imidocarbo |
BCP22333 |
1,3-bis(3-(4,5-dihydro-1h-imidazol-2-yl)phenyl)urea |
DB11521 |
Q908851 |
(s)-3-amino-3-(2-naphthyl)-propionicacid |
AMY13633 |
nsc-766768 |
nsc766768 |
EN300-7357087 |
imidocarbe (inn-french) |
dtxcid5028320 |
imidocarbum (inn-latin) |
imidocarb (mart.) |
imidocarbo (inn-spanish) |
imizol (veterinary) |
LS-14949 |
imizol |
MLS001336006 |
MLS001336005 , |
smr000875323 |
CHEMBL1315701 |
HMS2231C10 |
HMS3371N15 |
SCHEMBL1142888 |
Imidocarb (IMD) is a veterinary drug that has been used for more than 30 years to treat and prevent parasitic diseases.
Excerpt | Reference | Relevance |
---|---|---|
"Imidocarb (IMD) is a veterinary drug that has been used for more than 30 years to treat and prevent parasitic diseases. " | ( Determination of imidocarb residues in bovine and ovine liver and milk by immunobiosensor. Armstrong, L; Crooks, SR; Danaher, M; Fodey, T; Jordan, K; Kennedy, DG; Thompson, CS; Traynor, IM, 2013) | 2.17 |
Imidocarb, an effective treatment for piroplasmosis, may cause colic and diarrhoea in horses. Treatment was unsuccessful in one horse which remained infected as measured by nested PCR and retained the ability to infect a naïve recipient.
Imidocarb dipropionate (3,3'-bis[2-imidazolin-2-yl] carbanilide diproponate) was studied in calves injected twice intramuscularly with 0, 5, 10 or 20 mg/kg dosages. Results of this study suggest that glycopyrrolate is superior to atropine in ameliorating the adverse effects of imidocarb.
The objective of this study was to determine the pharmacokinetic behaviour of imidocarb in horses following a single i. The same dosage regimen can be used for clinical efficacy against Babesia spp.
Imidocarb was given intramuscular administration. The oral bioavailability of residues was determined in rats to evaluate the extent to which tissue imdocarb residues could be reabsorbed.
Excerpt | Reference | Relevance |
---|---|---|
" Additionally, the oral bioavailability of residues was determined in rats to evaluate the extent to which tissue imidocarb residues could be reabsorbed by consumers." | ( Depletion and bioavailability of imidocarb residues in sheep and goat tissues. Belloli, C; Cagnardi, P; Carofiglio, V; Crescenzo, G; Lai, O; Marangi, O; Ormas, P, 2002) | 0.81 |
Imidocarb, at a dosage of 4 mg/kg of body weight, given IM at 72-hour intervals 4 times, was ineffective in eliminating B equi-carrier infection in 9 mature geldings. Despite the differences in pharmacokinetic behavior, and considering the sensitivity of pathogens to imidOCarb, the same dosage regimen can be used for clinical efficacy against Babesia spp.
Excerpt | Relevance | Reference |
---|---|---|
" The drug alone had no deleterious effect on spermatogenesis when given intramuscularly 4 times at a dosage level of 4 mg/kg at 72-hour intervals." | ( Effect of imidocarb dipropionate and hemicastration on spermatogenesis in pony stallions. Frerichs, WM, 1977) | 0.66 |
" Imidocarb, at a dosage of 4 mg/kg of body weight, given IM at 72-hour intervals 4 times, was ineffective in eliminating B equi-carrier infection in 9 mature geldings." | ( Imidocarb and parvaquone in the treatment of piroplasmosis (Babesia equi) in equids. Gipson, CA; Kuttler, KL; Zaugg, JL, 1987) | 2.63 |
" Studies on the toxicology, residues and metabolism of IMDP showed this to be a safe dosage regimen." | ( Efficacy, toxicity and metabolism of imidocarb dipropionate in the treatment of Babesia ovis infection in sheep. Clampitt, RB; Crawley, RJ; James, JA; McHardy, N; Woollon, RM, 1986) | 0.54 |
" The majority of dogs showed some transient side-effects after administration of imidocarb, while a small proportion of dogs dosed with tetracycline reacted adversely and dosage had to be reduced or stopped." | ( A comparison of the efficacy of imidocarb dipropionate and tetracycline hydrochloride in the treatment of canine ehrlichiosis. Dolan, TT; Price, JE, 1980) | 0.77 |
" Transient, dosage dependent signs of toxicosis consisted of excessive salivation, serous nasal discharge, diarrhoea and dyspnoea." | ( A study of the toxicity of imidocarb dipropionate in cattle. Adams, LG; Corrier, DE; Williams, JD, 1980) | 0.56 |
" Several studies have shown that imidocarb remains detectable in edible ovine and bovine tissues for several months after dosing but the mechanism of retention remains unknown." | ( A cellular mechanism for imidocarb retention in edible bovine tissues. Coldham, NG; Moore, AS; Sauer, MJ, 1996) | 0.88 |
" Two sheep and 1 goat were slaughtered 15, 30, 60, 90 or 120 d after dosing and samples of muscle, injection site muscle, liver, omental and subcutaneous fat, and kidneys were collected." | ( Depletion and bioavailability of imidocarb residues in sheep and goat tissues. Belloli, C; Cagnardi, P; Carofiglio, V; Crescenzo, G; Lai, O; Marangi, O; Ormas, P, 2002) | 0.6 |
" Despite the differences in pharmacokinetic behavior, and considering the sensitivity of pathogens to imidocarb, the same dosage regimen can be used for clinical efficacy against Babesia spp." | ( Pharmacokinetics and mammary elimination of imidocarb in sheep and goats. Belloli, C; Crescenzo, G; Lai, OR; Ormas, P; Sasso, G; Zizzadoro, C, 2006) | 0.81 |
Role | Description |
---|---|
antiprotozoal drug | Any antimicrobial drug which is used to treat or prevent protozoal infections. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
ureas | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
TDP1 protein | Homo sapiens (human) | Potency | 8.2539 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
67.9K protein | Vaccinia virus | Potency | 31.6228 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 0.8199 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
snurportin-1 | Homo sapiens (human) | Potency | 0.8199 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 0.8199 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
plasminogen precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
geminin | Homo sapiens (human) | Potency | 12.5893 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 1.1220 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Glucose transporter | Leishmania mexicana | IC50 (µMol) | 12.0000 | 0.0810 | 2.3067 | 6.7450 | AID1207598 |
Hexose transporter 1 | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 (µMol) | 12.0000 | 0.0900 | 2.2220 | 5.8850 | AID1207597 |
Solute carrier family 2, facilitated glucose transporter member 1 | Homo sapiens (human) | IC50 (µMol) | 12.0000 | 0.0049 | 2.9954 | 9.9920 | AID1207599 |
Acetylcholinesterase | Homo sapiens (human) | IC50 (µMol) | 0.5900 | 0.0000 | 0.9332 | 10.0000 | AID482894 |
Calcium-dependent protein kinase 1 | Plasmodium falciparum 3D7 | IC50 (µMol) | 1.0000 | 0.0021 | 0.0076 | 0.0130 | AID1159502 |
Lysine--tRNA ligase | Plasmodium falciparum 3D7 | IC50 (µMol) | 2.5000 | 0.1200 | 0.1200 | 0.1200 | AID1159505 |
ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 11.8920 | 0.8730 | 10.7219 | 78.4000 | AID493155; AID493182 |
bcl-2-related protein A1 | Mus musculus (house mouse) | IC50 (µMol) | 20.0000 | 0.4190 | 7.7563 | 35.1000 | AID504689 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
PAX8 | Homo sapiens (human) | AC50 | 0.8790 | 0.0488 | 5.4354 | 69.1700 | AID687027 |
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7 | Homo sapiens (human) | AC50 | 20.7100 | 0.0398 | 15.0025 | 50.0000 | AID743267 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID543998 | Cytotoxicity against human HeLa cells assessed as cell detachment up to 60 uM after 3 hrs | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543996 | Toxicity in Yersinia pestis JG153 assessed as growth inhibition at 60 uM measured 6 mins intervals for 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID482894 | Inhibition of AChE | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods. |
AID240567 | Inhibitory activity towards acetylcholine esterase (AChE) | 2004 | Journal of medicinal chemistry, Sep-23, Volume: 47, Issue:20 | Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. |
AID543993 | Inhibition of T3SS-mediated YopD secretion in Yersinia pestis JG401 at 15 uM after 2 hrs by Western blotting | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543989 | Inhibition of T3SS-mediated YopM secretion in Yersinia pestis JG401 after 2 hrs by Western blotting | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543991 | Inhibition of T3SS-mediated YopH secretion in Yersinia pestis JG401 after 2 hrs by Western blotting | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543992 | Inhibition of T3SS-mediated YopD secretion in Yersinia pestis JG401 at up to 60 uM after 2 hrs by Western blotting | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543994 | Inhibition of T3SS-mediated YopD secretion in Yersinia pestis JG401 after 2 hrs by Western blotting | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543997 | Cytotoxicity against human HeLa cells assessed as cell rounding up to 60 uM after 3 hrs | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID544002 | Inhibition of T3SS-mediated Tir secretion in enteropathogenic Escherichia coli KC14 harboring pKC17 at after 2 hrs by Western blotting | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543995 | Inhibition of T3SS-mediated YopM secretion in Yersinia pestis JG401 t up to 60 uM after 2 hrs by Western blotting | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543999 | Cytotoxicity against human HeLa cells assessed as LDH release up to 60 uM after 3 hrs | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID543990 | Inhibition pCD1 positive Yersinia pestis JG153 T3SS-mediated morphological changes in human HeLa cells after 3 hrs | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID1159585 | Biochemical screen of P. falciparum CDPK1 | 2016 | PloS one, , Volume: 11, Issue:3 | Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. |
AID1159588 | Biochemical screen of P. falciparum CDPK4 | 2016 | PloS one, , Volume: 11, Issue:3 | Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. |
AID1159587 | Biochemical screen of P. falciparum PK7 | 2016 | PloS one, , Volume: 11, Issue:3 | Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. |
AID1159589 | Biochemical screen of P. falciparum MAPK2 | 2016 | PloS one, , Volume: 11, Issue:3 | Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. |
AID1159586 | Biochemical screen of P. falciparum PK6 | 2016 | PloS one, , Volume: 11, Issue:3 | Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID544001 | Inhibition of translocation of YopE::Bla fusion from pMM85 expressing Yersinia pestis JG153 to human HeLa cells at 40 uM after 3 hrs by fluorescence microscopic analysis | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID562734 | Antiparasitic activity against Babesia caballi infected in horse assessed as reduction in parasite specific antibodies at 4 mg/kg, im dosed 4 times at 72 hrs intervals administered 70 days postinfection measured 201 days post dose by C-ELISA | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID562730 | Antiparasitic activity against Babesia caballi receiving ticks from 4 times 4 mg/kg, im compound treated donor horse infected with Babesia caballi assessed as reduction in parasite specific antibodies measured after 100 days post-parasite transmission by | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID562732 | Antiparasitic activity against Babesia caballi infected in horse assessed as reduction in parasite level at 4 mg/kg, im dosed 4 times at 72 hrs intervals administered 70 days postinfection and measured 5 days post last dose by nested PCR | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID562728 | Antiparasitic activity against Babesia caballi receiving blood from 4 times 4 mg/kg, im compound treated donor horse infected with Babesia caballi assessed as reduction in parasite specific antibodies measured after 100 days post-parasite transmission by | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID544000 | Inhibition of translocation of YopE::Bla fusion from pMM85 expressing Yersinia pestis JG153 to human HeLa cells at 80 uM after 3 hrs by fluorescence microscopic analysis | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Targeting type III secretion in Yersinia pestis. |
AID562727 | Antiparasitic activity against Babesia caballi receiving blood from 4 times 4 mg/kg, im compound treated donor horse infected with Babesia caballi assessed as reduction in parasite level measured after 100 days post-parasite transmission by nested PCR | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID562733 | Antiparasitic activity against Babesia caballi infected in horse assessed as reduction in parasite specific antibodies at 4 mg/kg, im dosed 4 times at 72 hrs intervals administered 70 days postinfection measured 56 days post dose by complement fixation as | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID562731 | Antiparasitic activity against Babesia caballi infected in horse assessed as reduction in parasite level at 4 mg/kg, im dosed 4 times at 72 hrs intervals administered 70 days postinfection and measured 5 days post last dose by quantitative PCR | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID562729 | Antiparasitic activity against Babesia caballi receiving ticks from 4 times 4 mg/kg, im compound treated donor horse infected with Babesia caballi assessed as reduction in parasite level measured after 100 days post-parasite transmission by nested PCR | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
AID562735 | Antiparasitic activity against Babesia caballi infected in horse assessed as reduction in parasite specific antibodies at 4 mg/kg, im dosed 4 times at 72 hrs intervals administered 70 days postinfection measured 222 days post dose by immunoblot | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 57 (28.79) | 18.7374 |
1990's | 27 (13.64) | 18.2507 |
2000's | 52 (26.26) | 29.6817 |
2010's | 51 (25.76) | 24.3611 |
2020's | 11 (5.56) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (66.70) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 16 (7.84%) | 5.53% |
Trials | 0 (0.00%) | 5.53% |
Reviews | 5 (2.45%) | 6.00% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 34 (16.67%) | 4.05% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Observational | 0 (0.00%) | 0.25% |
Other | 149 (73.04%) | 84.16% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |